DV
Dividend Vision

ACOG — Alpha Cognition Inc

Alpha Cognition Inc (ACOG)

Total return is 5.2% over the past 1.8 years, 27.1 points behind SPY at 32.3%. Its deepest 1-year drawdown was 55.0%.

Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases, including Alzheimer's disease, mild traumatic brain injury, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead program is ZUNVEYL, an oral tablet formulation for Alzheimer's disease in commercial development, along with several pre-clinical candidates in various formulations. The company does not currently distribute dividends and is focused on drug development rather than generating current income.

ACOG key facts

Asset type
Stock
Asset class
Equity
Inception date
11/11/2024
Last close
$8.84
Market cap
$185,079,888
Average volume
247600.0
Beta
2.333
Payout ratio
0.0
Forward P/E
26.8817
EPS
$-1.39